Multiple Risk Factors in Cardiovascular Disease

Preface. I: Multiple Risk Factors in Population. 1. Lipid Risk Factors and the Regression of Atherosclerosis; A. M. Gotto Jr. 2. Multiple Risk Factors: What is Next? M. Higgins, C. Lenfant 3. Multiple Risk Factors in Northern Italy; G. A. Feruglio, D. Vanuzzo, G. Cesana, M. Ferrario on behalf of the MONICA- Friuli and MONICA-Brianza Study Groups. 4. Long-Term Associations between Hemostatic Variables and Ischemic Heart Disease; T. W. Meade. 5. Cardiovascular Gene Therapy: Possibilities and Realities; V. J. Dzau, R. Morishita, G. H. Gibbons. 6. Triglycerides and Coronary Heart Disease: An Update; M. H. Criqui. II: Lipids and Lipoproteins. 7. Factors Controlling Lipoprotein Metabolism; E. Sehayek, S. Eisenberg. 8. Apolipoproteins in the Treatment of Vascular and Nonvascular Disease; C. R. Sirtori. 9. Explorations of Postprandial Lipids in a Case of Homozygous APO B45.2; B. Jacotot, A. Piolot, M. Ayraut-Jarrier, N. Lemort, C. Martin, S. Braschi, F. Yen, B. Bihain. 10. Apolipoprotein E Binding and Hepatic Lipase-Mediated Catabolism Make Alternate Pathways in the Metabolism of Intermediate Lipoprotein Particles: Observation in Patients with Hepatic Lipase Deficiency; A. Yamamoto, Y. Ikeda, Z. Tsutsumi, A. Mori, A. Takagi, M. Tsushima. III: Critical Aspects of Vascular Protection of New Dihydropyridine Calcium Antagonists. 11. New Aspects of the Pharmacology of Dihydropyridine Calcium Antagonists; T. Godfraind, O. Feron, N. Morel, S. Salomone, M. Wibo. 12. Membrane Interaction of Lipophilic Dihydropyridines as New Mechanisms for Vascular Protection; G. Gaviraghi, D. Trist. 13. Mechanisms of Free Radical Oxidations and Vascular Damage: Protective Effect of Dihydropyridines; F. Ursini. 14. Lipophilic Dihydropyridines: New Opportunities for Prevention of Atherosclerosis; R. Paoletti. 15. Clinical Trial Design and Noninvasive Atherosclerosis Endpoints for Studying Lipophilic Dihydropyridines; M. G. Bond, M. Mercuri, R. Arens, F. Gianfrate for the ELSA Collaborative Research Group. IV: N-3 Fatty Acids and Cardiovascular Risk Factors. 16. The Biological Roles of n-e Fatty Acids: Metabolic and Nutritional Aspects; C. Galli. 17. Effect of Supplementation with Moderate Doses of n-3 Fatty Acid Ethyl Esters to Hypertriglyceridemic Patients on Lipid and Hemostatic Variables; E. Tremoli, S. Colli, P. Maderna, S. Eligini, E. Stragliotto, P. Risé, F. Pazzucconi, C. R. Sirtori, C. Galli. 18. Long-Lasting Inhibition of Platelet Aggregation Following a Relatively Short-Course Administration of n-3 Fatty Acid Ethyl Esters; A. M. Cerbone, T. Cusano, E. Tremoli, C. Galli, F. Cirillo, A. Coppola, E. Stragliotto, A. Amoriello, V. Marottoli, G. Vecchione, G. Di Minno. V: Diabetes. 19. Insulin Resistance and Cardiovascular Risk Factors in Noninsulin-Dependent Diabetes Mellitus; K. G. M. M. Alberti. 20. Glucose as a Risk Factor for Atherosclerosis; R. Bucala, A. Cerami. 21. Dyslipidemia in NIDDM: New Insights; M.-R. Taskinen, M. Syvänne, S. Lahdenperä. 22. Diabetes and Cardiovascular Risk: Epidemiological Aspects; S. M. Haffner. 23. Rational Treatment of the `Plurimetabolic Syndrome'; A. Tiengo, A. Avogaro, S. Del Prato. 24. Kidney Protection in Diabetes Mellitus; K. H. Rahn, M. Barenbrock, B. Suwelack, H. Hohage. 25. Association of Serum Uric Acid with Triglyceride Levels in Female Patients with NIDDM; W. Rathmann, H. Hauner, B. Haastert, K. Kirchner, F. A. Gries. 26. Cardiovascular Disease Prevention in the Elderly; G. Crepaldi, E. Manzato. VI: Diabetic Dyslipidemia and Atherosclerosis: Current Clinical Findings and Treatment Strategies. 27. Insulin Resistance and Coronary Heart Disease; G. M. Reaven. 28. Diabetic Dyslipidemia: The Asian Perspective; T.-Y. Tai, C.-J. Change, Y.-T. Lee. 29. Therapeutic Intervention in Diabetic Dyslipidemia; A. M. Gotto Jr. VII: Hypertension. 30. Red Blood Cell Cation Heteroexchange and Cardiovascular Risk; A. Semplicini, G. Ceolotto, M. Felice, A. Gebbin, A. Fontebasso, R. Valle, L. Serena, C. Dal Palù. 31. Hypertension in the Elderly with Special Focus on Side Effects; L. H. Lindholm. VIII: Therapeutic Interventions. 32. Drugs Directly Affecting the Arterial Wall; R. Paoletti, M. R. Soma. 33. The POSCH Trial: Importance of Cholesterol Lowering in Reducing Coronary Heart Disease Progression; C. T. Campos, H. Buchwald, the POSCH Group. 34. Three-Dimensional Reconstruction of Intracoronary Ultrasound Images: Technical Approaches, Clinical Applications, and Current Limitations in the Assessment of Vessel Dimensions; C. von Birgelen, C. Di Mario, W. Li, F. Prati, N. Bom, J. R. T. C. Roelandt, P. W. Serruys. IX: New Trends in the Use of Fibrates. 35. Metabolic Basis of the Atherogenic Lipoprotein Phenotype; C. J. Packard, J. Shepherd. 36. Fibrates: Modes of Action; A. L. Catapano. 37. Fenofibrate: A Safety Evaluation of a Large German Patient Population; K. U. Kirschgässler. X: New Insights on Cholesterol Controversy. 38. Plasma Cholesterol and Total Mortality; R. Paoletti, A. Poli. 39. Cholesterol-Lowering Coronary Angiography Trials: An Overview; L. J. Hirsch. 40. Treatment of Hyperlipidemia in Specific Types of Patients: The Elderly, Women, and Patients with Coronary Heart Disease; D. R. Illingworth. 41. An Italian Multicenter Study on the Efficacy and Tolerability of Simvastatin in Male Patients with Essential Hypertension and Primary Hypercholesterolemia; A. Salvetti, G. Argenio, G. Bernini. 42. Effects of Simvastatin Treatment on Thromboxane (TX) Biosynthesis and Platelet Function in Type II Hypercholesterolemia (HC); A. Notarbartolo. XI: Risk Factors. 43. Risk Factor Interactions Involving Pressor Agents; G. V. R. Born, L. E. Cardona-Sanclemente. 44. Hemodynamic and Adrenergic Effects of Cigarette Smoking; G. Grassi, A. Lanfranchi, S. Vailati, G. Seravalle, B. M. Cattaneo, G. Mancia. 45. Serum Uric Acid and 18-Year Cardiovascular Mortality in the Chicago Heart Association Detection Project in Industry; A. R. Dyer, R. Stamler, J. Stamler, D. Garside. 46. The Impact of High-Density Lipoprotein Cholesterol on Cardiovascular Risk: The Bezafibrate Infarction Prevention (BIP) Study; U. Goldbourt for the BIP Study Research Group. 47. Triglycerides and the Fibrinolytic System; E. Tremoli, L. Sironi, M. Camera, L. Mannucci, L. Prati, C. Banfi, D. Baldassare, L. Mussoni. 48. Apolipoprotein E and Alzheimer's Disease; G. Franceschini, L. Calabresi, C. R. Sirtori, G. B. Frisoni, C. Geroldi, A. Bianchetti, M. Trabucchi, S. Govoni. 49. Apolipoprotein A1: A Natural Kidney-Protective Agent? J. R. Paterniti, Jr., B. F. Burkey, D. France, H. Wong, X. Ma, B. Brand, C. Abuhani, M. R. Diffenderfer, J. B. Marsh, E. A. Fisher. XII: Vascular Reactivity and Remodeling. 50. Noninvasive Evaluation of Arterial Reactivity in Patients with Premature Onset Coronary Disease; P. Rubba, C. Sapio, P. Pauciullo, A. Iannuzzi, G. Iannuzzo, D. Iorio, N. Spampinato, M. Mancini. 51. Long-Chain Acylcarnitine as Membrane Stabilizer; W. C. Hülsmann, A. Peschechera. XIII: Protective Effects of Moderate Consumption of Alcohol on the Incidence of Coronary Heart Disease. 52. Protective Effects of Moderate Consumption of Alcohol on the Incidence of Coronary Heart Disease; M. H. Criqui. 53. Alcohol Consumption: Weighing the Cardiovascular Benefit with the Overall Health Risk; E. B. Rimm. 54. Alcohol and Atherosclerosis; A. Catapano. Index.